Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 17/20 | 0.46 |
| ▸ | FLT3 | P36888 | 3/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26136086 | 0.95 | SYK (0.47) | SYKFLT3AURKBIRAK4 | |
| SCHEMBL31676292 | 0.86 | SYK (0.46) | SYKAURKB | |
| SCHEMBL31675948 | 0.86 | SYK (0.46) | SYKAURKB | |
| SCHEMBL31676444 | 0.86 | SYK (0.46) | SYKAURKB | |
| SCHEMBL26136072 | 0.85 | SYK (0.52) | SYKFLT3AURKBIRAK4 | |
| SCHEMBL31676390 | 0.84 | SYK (0.45) | SYKFLT3AURKBEPHA2KDR | |
| SCHEMBL31676143 | 0.84 | SYK (0.48) | SYKEPHA2KDREPHB4IRAK4 | |
| SCHEMBL31676114 | 0.83 | SYK (0.46) | SYKFLT3AURKBEPHB4 | |
| SCHEMBL31675960 | 0.83 | SYK (0.44) | SYKFLT3AURKB | |
| SCHEMBL31676296 | 0.82 | SYK (0.45) | SYKFLT3AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2025-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | LCK, BTK, SYK | SYK 3/4885FLT3 12/4885AURKB 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.